Research graph
References from Interim efficacy and preliminary survival outcomes of polatuzumab vedotin in combination for diffuse large B-cell lymphoma: a retrospective real-world study. Local targets link to admitted publications; unresolved targets remain external evidence.
How I treat diffuse large B-cell lymphoma
10.1016/j.esmoop.2022.100750 · 2023 · External reference
Fifth edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: B-cell neoplasms
10.1016/j.modpat.2024.100441 · 2024 · External reference
First-line combination of R-CHOP with the PDE4 inhibitor roflumilast for high-risk DLBCL
10.3390/cancers16223857 · 2024 · External reference
Refractory DLBCL: challenges and treatment
10.1016/j.clml.2021.09.011 · 2022 · External reference
Advances in biology, diagnosis and treatment of DLBCL
10.1007/s00277-024-05880-z · 2024 · External reference
Management of primary refractory diffuse large B-cell lymphoma in patients unsuitable for CAR T-cell therapy
10.1111/ejh.70153 · 2026 · External reference
B-cell receptor signaling and beyond: The role of Igα (CD79a)/Igβ (CD79b) in normal and Malignant B cells
10.3390/ijms25010010 · 2023 · External reference
Polatuzumab vedotin: A new target for B cell Malignancies
10.1007/s11899-020-00572-7 · 2020 · External reference
Polatuzumab vedotin: First global approval
10.1007/s40265-019-01175-0 · 2019 · External reference
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
10.1182/blood-2003-05-1545 · 2004 · External reference
Toxicity and response criteria of the Eastern Cooperative Oncology Group
10.1097/00000421-198212000-00014 · 1982 · External reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification
10.1200/jco.2013.54.8800 · 2014 · External reference
A predictive model for aggressive non-Hodgkin’s lymphoma
10.1056/nejm199309303291402 · 1993 · External reference
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: A real-world experience
10.1007/s00277-021-04711-9 · 2022 · External reference
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
10.1182/blood-2013-09-524108 · 2014 · External reference
Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
10.1056/nejmoa2115304 · 2022 · External reference
Real‐world outcomes of polatuzumab vedotin plus R‐CHP versus R‐CHOP‐based regimens in Japanese patients with untreated diffuse large B‐cell lymphoma
10.1002/cam4.71531 · 2026 · External reference
Efficacy and relapse profiles of Pola‐R‐CHP versus R‐CHOP in previously untreated diffuse large B‐cell lymphoma: A multicentre real‐world study
10.1111/bjh.70280 · 2026 · External reference
Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B‐cell lymphoma: A real‐world, multi‐center, retrospective cohort study
10.1002/hon.70017 · 2025 · External reference
Polatuzumab vedotin in previously untreated DLBCL: An Asia subpopulation analysis from the phase 3 POLARIX trial
10.1182/blood.2022017734 · 2023 · External reference
Mid-treatment response to 177-lutetium dotatate predicts overall outcome in patients with advanced neuroendocrine tumors
10.1200/op.23.00789 · 2024 · External reference
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia
10.1002/ajh.25712 · 2020 · External reference
Factors affecting survival in elderly patients with diffuse large B-cell lymphoma
10.1016/j.leukres.2021.106700 · 2021 · External reference
The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era
10.1111/cas.16377 · 2025 · External reference
Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index
10.1182/blood-2007-01-070300 · 2007 · External reference
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
10.1182/bloodadvances.2023011408 · 2024 · External reference
Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients
10.1100/2012/897178 · 2012 · External reference
Cell-of-origin subtype predicts response to polatuzumab vedotin in large B-cell lymphoma
10.1158/1078-0432.ccr-25-2392 · 2026 · External reference
Impact of response to holding/bridging therapy in second‐line DLBCL patients treated with axicabtagene ciloleucel: A LYSA study from the French DESCAR‐T registry
10.1002/hon.70094_446 · 2025 · External reference
The implications of non‐compliance: Randomised controlled trials: The intention‐to‐treat principle
10.1111/1471-0528.15505 · 2019 · External reference
Rethinking the intention-to-treat principle: One size does not fit all
10.1016/j.jclinepi.2020.04.023 · 2020 · External reference
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology
10.1182/blood-2017-12-820605 · 2018 · External reference
